PriceTargets.com logo

Arvinas - ARVN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $78.69
  • Forecasted Upside: 90.43 %
  • Number of Analysts: 17
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 14 Buy Ratings
  • 0 Strong Buy Ratings
$41.32 As of 11/30/2022 05:04 PM ET
▲ +3.03 (7.91%)

This chart shows the closing price for ARVN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arvinas Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARVN

Analyst Price Target is $78.69
▲ +90.43% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Arvinas in the last 3 months. The average price target is $78.69, with a high forecast of $102.00 and a low forecast of $42.00. The average price target represents a 90.43% upside from the last price of $41.32.

This chart shows the closing price for ARVN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 17 investment analysts is to buy stock in Arvinas. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2021
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2021
  • 0 strong buy ratings
  • 16 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2022
  • 0 strong buy ratings
  • 16 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/2/2022
  • 0 strong buy ratings
  • 13 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2022
  • 0 strong buy ratings
  • 14 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2022
  • 0 strong buy ratings
  • 14 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/29/2022

Latest Recommendations

  • 0 strong buy ratings
  • 14 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/28/2022The Goldman Sachs GroupReiterated RatingBuy$81.00Low
11/23/2022Truist FinancialLower Target$170.00 ➝ $100.00Low
11/23/2022Cantor FitzgeraldLower Target$106.00 ➝ $90.00Low
11/23/2022BarclaysLower TargetOverweight$90.00 ➝ $70.00Low
11/22/2022Piper SandlerBoost TargetOverweight$76.00 ➝ $81.00Low
11/22/2022SVB LeerinkLower TargetOutperform$89.00 ➝ $74.00Low
11/15/2022Credit Suisse GroupBoost Target$81.00N/A
11/11/2022Morgan StanleyLower TargetEqual Weight$63.00 ➝ $57.00Low
10/25/2022Capital One FinancialInitiated CoverageOverweightLow
10/18/2022Stifel NicolausReiterated RatingBuy ➝ Buy$80.00Low
9/21/2022Cantor FitzgeraldReiterated RatingOverweightLow
9/9/2022BarclaysInitiated CoverageOverweight$90.00Low
8/18/2022CitigroupLower Target$103.00 ➝ $88.00Low
8/8/2022OppenheimerLower TargetOutperform$108.00 ➝ $102.00Low
8/5/2022Cantor FitzgeraldLower Target$140.00 ➝ $115.00Low
8/5/2022SVB LeerinkLower TargetOutperform$91.00 ➝ $89.00Low
8/5/2022Credit Suisse GroupLower TargetOutperform$98.00 ➝ $78.00Low
8/5/2022HC WainwrightLower TargetBuy$135.00 ➝ $90.00Low
6/21/2022Jefferies Financial GroupInitiated CoverageHold$42.00Low
5/24/2022The Goldman Sachs GroupLower TargetBuy$111.00 ➝ $89.00Low
5/23/2022Piper SandlerLower TargetOverweight$116.00 ➝ $76.00High
5/20/2022CitigroupLower TargetBuy$103.00Low
5/9/2022WedbushDowngradeOutperform ➝ Neutral$43.00High
5/5/2022Stifel EuropeLower TargetBuy ➝ Buy$85.00 ➝ $82.00High
4/28/2022Credit Suisse GroupInitiated CoverageOutperform$104.00High
4/26/2022Stifel NicolausLower Target$93.00 ➝ $85.00High
4/6/2022Morgan StanleyInitiated CoverageEqual Weight$65.00Medium
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
3/1/2022Stifel NicolausLower TargetBuy$100.00 ➝ $93.00Medium
3/1/2022The Goldman Sachs GroupLower TargetBuy$157.00 ➝ $110.00Medium
2/18/2022WedbushLower Target$115.00 ➝ $98.00Low
2/18/2022SVB LeerinkLower TargetOutperform$97.00 ➝ $91.00Low
2/10/2022Wells Fargo & CompanyInitiated CoverageOverweight$98.00High
1/19/2022The Goldman Sachs GroupInitiated CoverageBuy$157.00Low
12/6/2021CowenInitiated CoverageOutperformLow
11/4/2021OppenheimerUpgradeMarket Perform ➝ OutperformHigh
10/14/2021SVB LeerinkInitiated CoverageOutperform$115.00High
9/29/2021Stifel NicolausInitiated CoverageBuy$115.00Low
9/9/2021Bank of AmericaInitiated CoverageBuy$110.00High
8/9/2021Roth CapitalBoost TargetBuy$120.00 ➝ $135.00Medium
8/5/2021Piper SandlerBoost TargetOverweight ➝ Overweight$105.00 ➝ $125.00High
7/23/2021BMO Capital MarketsBoost TargetOutperform$101.00 ➝ $111.00High
7/23/2021CitigroupBoost TargetBuy$118.00 ➝ $153.00High
7/23/2021HC WainwrightReiterated RatingBuy$100.00 ➝ $135.00High
7/23/2021OppenheimerBoost TargetOutperform$100.00 ➝ $108.00High
7/22/2021Piper SandlerReiterated RatingOverweight$97.00 ➝ $105.00High
7/22/2021Truist FinancialBoost TargetBuy$150.00 ➝ $170.00High
5/20/2021UBS GroupInitiated CoverageBuy$123.00High
4/21/2021Northern Trust Capital MarketsInitiated CoverageBuyLow
4/21/2021Truist FinancialInitiated CoverageBuy$150.00High
3/31/2021BMO Capital MarketsInitiated CoverageOutperform$101.00High
3/30/2021Cantor FitzgeraldBoost TargetOverweight$121.00 ➝ $140.00High
1/19/2021OppenheimerBoost Target$80.00 ➝ $100.00Low
1/5/2021Cantor FitzgeraldBoost TargetOverweight$66.00 ➝ $121.00N/A
12/21/2020Piper SandlerBoost TargetOverweight$58.00 ➝ $97.00Low
12/15/2020Smith Barney CitigroupBoost Target$43.00 ➝ $123.00High
12/15/2020Roth CapitalBoost TargetBuy$65.00 ➝ $120.00High
12/14/2020HC WainwrightReiterated RatingBuy$60.00 ➝ $100.00High
12/14/2020BMO Capital MarketsBoost TargetOutperform$62.00 ➝ $114.00High
12/14/2020OppenheimerUpgradeMarket Perform ➝ OutperformHigh
12/14/2020The Goldman Sachs GroupBoost TargetBuy$78.00 ➝ $129.00High
12/14/2020WedbushBoost TargetOutperform$62.00 ➝ $93.00High
12/1/2020Cantor FitzgeraldLower Target$75.00 ➝ $66.00Medium
10/9/2020Cantor FitzgeraldReiterated RatingOverweightHigh
10/8/2020OppenheimerReiterated RatingHoldHigh
8/4/2020OppenheimerInitiated CoverageHoldLow
6/1/2020CitigroupUpgradeNeutral ➝ Buy$45.00Medium
5/31/2020OppenheimerInitiated CoverageHoldLow
5/29/2020Cantor FitzgeraldReiterated RatingBuy$75.00Low
5/14/2020Cantor FitzgeraldReiterated RatingBuy$75.00Medium
5/11/2020OppenheimerInitiated CoverageMarket PerformMedium
5/4/2020Roth CapitalBoost TargetBuy$35.00 ➝ $65.00High
4/29/2020HC WainwrightReiterated RatingBuy$50.00 ➝ $60.00Medium
4/14/2020Cantor FitzgeraldReiterated RatingBuy$75.00Low
3/16/2020Piper SandlerReiterated RatingBuy$58.00High
1/30/2020BMO Capital MarketsReiterated RatingOutperform$62.00High
1/24/2020WedbushBoost TargetOutperform$39.00 ➝ $60.00Medium
1/6/2020Piper Jaffray CompaniesBoost TargetOverweight$35.00 ➝ $58.00N/A
12/20/2019Cantor FitzgeraldBoost TargetOverweight$42.00 ➝ $75.00Low
12/19/2019HC WainwrightInitiated CoverageBuy$50.00High
11/25/2019GuggenheimInitiated CoverageBuy$50.00High
11/14/2019Roth CapitalInitiated CoverageBuy$35.00Medium
11/13/2019Piper Jaffray CompaniesReiterated RatingBuy$32.00 ➝ $35.00High
10/24/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$23.00 ➝ $38.00Medium
9/24/2019WedbushInitiated CoverageOutperform$35.00 ➝ $38.00Low
9/12/2019BMO Capital MarketsInitiated CoverageOutperform$34.00High
8/5/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$42.00 ➝ $42.00Medium
6/5/2019CitigroupDowngradeBuy ➝ Neutral$21.00 ➝ $22.00High
5/8/2019Piper Jaffray CompaniesBoost TargetOverweight$23.00 ➝ $32.00High
4/11/2019Evercore ISIInitiated CoverageOutperformHigh
10/22/2018CitigroupInitiated CoverageBuy ➝ Buy$21.00Low
10/22/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$17.00High
10/22/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$23.00High
(Data available from 11/30/2017 forward)

News Sentiment Rating

0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 10 negative mentions
  • 2 very negative mentions
Mentions as of
6/3/2022
  • 1 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2022
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
9/1/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 1 very positive mentions
  • 10 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
11/30/2022

Current Sentiment

  • 1 very positive mentions
  • 10 positive mentions
  • 6 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Arvinas logo
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Read More

Today's Range

Now: $41.32
Low: $38.53
High: $41.35

50 Day Range

MA: $44.88
Low: $38.29
High: $57.24

52 Week Range

Now: $41.32
Low: $34.90
High: $83.40

Volume

22,898 shs

Average Volume

568,267 shs

Market Capitalization

$2.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Arvinas?

The following Wall Street research analysts have issued reports on Arvinas in the last year: Barclays PLC, Cantor Fitzgerald, Capital One Financial Co., Citigroup Inc., Cowen Inc, Credit Suisse Group AG, HC Wainwright, Jefferies Financial Group Inc., Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Stifel Europe, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist Financial Co., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for ARVN.

What is the current price target for Arvinas?

16 Wall Street analysts have set twelve-month price targets for Arvinas in the last year. Their average twelve-month price target is $78.69, suggesting a possible upside of 103.8%. Oppenheimer Holdings Inc. has the highest price target set, predicting ARVN will reach $102.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $42.00 for Arvinas in the next year.
View the latest price targets for ARVN.

What is the current consensus analyst rating for Arvinas?

Arvinas currently has 3 hold ratings and 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARVN will outperform the market and that investors should add to their positions of Arvinas.
View the latest ratings for ARVN.

What other companies compete with Arvinas?

Other companies that are similar to Arvinas include Akero Therapeutics, Xenon Pharmaceuticals, Sage Therapeutics, Arcus Biosciences and Pacira BioSciences. Learn More about companies similar to Arvinas.

How do I contact Arvinas' investor relations team?

Arvinas' physical mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company's listed phone number is (203) 535-1456 and its investor relations email address is [email protected] The official website for Arvinas is www.arvinas.com. Learn More about contacing Arvinas investor relations.